Literature DB >> 9379024

Cellular requirements for the activation and proliferation of ruminant gammadelta T cells.

C F Hanrahan1, W G Kimpton, C J Howard, K R Parsons, M R Brandon, A E Andrews, A D Nash.   

Abstract

Requirements for the activation and proliferation of gammadelta T cells were investigated. Maximum numbers of gammadelta T cells expressed the IL-2R alpha-chain after 6-h Con A stimulation in peripheral blood, efferent lymph, and afferent lymph. In comparison, IL-2R alpha-chain expression on CD4 T cells only reached maximum levels in response to Con A stimulation in peripheral blood and afferent lymph populations. Analysis of enriched gammadelta T cells demonstrated that Con A-induced expression of the IL-2R alpha-chain was independent of APC. Together, these data suggest that the requirements for gammadelta T cell activation are less stringent than those for alphabeta T cell activation. Unfractionated peripheral blood, efferent lymph, and afferent lymph cell populations proliferated in response to Con A alone. In contrast, enriched gammadelta T cells (CD4/CD8 depleted) from efferent lymph did not proliferate in response to Con A alone, but required the addition of IL-2. This requirement for exogenous IL-2 could be overcome by the addition of dendritic cells purified from afferent lymph. These results suggested that gammadelta T cells required costimulatory signals provided by APC to ensure the production of sufficient IL-2 to drive proliferation. CD28 and CTLA-4 mRNA were detected in efferent lymph and afferent lymph populations containing CD4 and CD8 T cells stimulated with Con A and IL-2 or with Con A alone, respectively. In contrast, negligible levels of these mRNA species were detected in efferent and afferent lymph populations devoid of CD4 and CD8 T cells. These results suggest that ovine gammadelta T cells may use alternative costimulatory pathways.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9379024

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Local immune responses in afferent and efferent lymph.

Authors:  D M Haig; J Hopkins; H R Miller
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

Review 2.  Searching for "signal 2": costimulation requirements of γδ T cells.

Authors:  Julie C Ribot; Ana debarros; Bruno Silva-Santos
Journal:  Cell Mol Life Sci       Date:  2011-05-04       Impact factor: 9.261

3.  Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.

Authors:  Drew C Deniger; Kirsten Switzer; Tiejuan Mi; Sourindra Maiti; Lenka Hurton; Harjeet Singh; Helen Huls; Simon Olivares; Dean A Lee; Richard E Champlin; Laurence J N Cooper
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

4.  Workshop cluster 1+ gammadelta T-cell receptor T cells from calves express high levels of interferon-gamma in response to stimulation with interleukin-12 and -18.

Authors:  Sally J Price; Paul Sopp; Christopher J Howard; Jayne C Hope
Journal:  Immunology       Date:  2006-10-11       Impact factor: 7.397

5.  Activated gammadelta T cells promote the activation of uveitogenic T cells and exacerbate EAU development.

Authors:  Hong Nian; Hui Shao; Rebecca L O'Brien; Willi K Born; Henry J Kaplan; Deming Sun
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

6.  Immunological characterization of a gammadelta T-cell stimulatory ligand on autologous monocytes.

Authors:  Thillainayagam Sathiyaseelan; Brian Naiman; Stefan Welte; Niall Machugh; Samuel J Black; Cynthia L Baldwin
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

7.  Enhanced secretion of interferon-gamma by bovine gammadelta T cells induced by coculture with Mycobacterium bovis-infected dendritic cells: evidence for reciprocal activating signals.

Authors:  Sally J Price; Jayne C Hope
Journal:  Immunology       Date:  2008-07-22       Impact factor: 7.397

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.